Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from Brokerages

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has earned an average rating of "Buy" from the eight research firms that are covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.60.

A number of analysts have issued reports on the company. Wall Street Zen downgraded Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. B. Riley reissued a "buy" rating and issued a $5.00 target price (down from $6.00) on shares of Immunic in a report on Friday, May 23rd. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Immunic in a research note on Thursday, May 1st. D. Boral Capital reiterated a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday, June 5th. Finally, William Blair restated an "outperform" rating on shares of Immunic in a research report on Friday, May 16th.

Institutional Investors Weigh In On Immunic

Hedge funds have recently bought and sold shares of the stock. Focus Partners Wealth increased its stake in shares of Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock valued at $2,816,000 after purchasing an additional 415,104 shares in the last quarter. Jane Street Group LLC grew its holdings in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after purchasing an additional 152,726 shares during the period. 683 Capital Management LLC increased its position in shares of Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock valued at $981,000 after buying an additional 200,000 shares in the last quarter. Aberdeen Group plc acquired a new position in shares of Immunic during the 1st quarter worth approximately $1,155,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after buying an additional 96,894 shares during the period. Hedge funds and other institutional investors own 51.82% of the company's stock.

Immunic Price Performance

Shares of IMUX traded down $0.02 on Wednesday, reaching $0.87. The company's stock had a trading volume of 932,861 shares, compared to its average volume of 875,014. The stock has a market capitalization of $83.36 million, a P/E ratio of -0.71 and a beta of 1.48. The stock's 50 day simple moving average is $0.95 and its two-hundred day simple moving average is $1.05. Immunic has a 12-month low of $0.56 and a 12-month high of $2.11.

Immunic (NASDAQ:IMUX - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.25). Analysts expect that Immunic will post -0.94 earnings per share for the current year.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.